ERBB2 and ductal breast carcinoma in situ: HER2+ and EGFR+ primary DCIS tumors with a known recurrence were associated with a halved risk of the recurrence being invasive OR 0.48, 95% CI 0.26–0.90 and OR 0.44, CI 0.22–0.88, respectively.